Why Johnson & Johnson (NYSE:JNJ) Could Be Your Next Investment

Johnson & Johnson (NYSE:JNJ) is a stock with outstanding fundamental characteristics. When we build an investment case, we need to look at the stock with a holistic perspective. In the case of JNJ, it is a notable dividend payer with a great history of delivering benchmark-beating performance. Below, I've touched on some key aspects you should know on a high level. If you're interested in understanding beyond my broad commentary, take a look at the report on Johnson & Johnson here.

Advertisement

Solid track record established dividend payer

In the past couple of years, JNJ has ramped up its bottom line by over 100%, with its latest earnings level surpassing its average level over the last five years. This illustrates a strong track record, leading to a satisfying return on equity of 28%, which is an optimistic signal for the future.

NYSE:JNJ Income Statement, July 29th 2019
NYSE:JNJ Income Statement, July 29th 2019

For those seeking income streams from their portfolio, JNJ is a robust dividend payer as well. Over the past decade, the company has consistently increased its dividend payout, reaching a yield of 2.9%.

NYSE:JNJ Historical Dividend Yield, July 29th 2019
NYSE:JNJ Historical Dividend Yield, July 29th 2019

Next Steps:

For Johnson & Johnson, I've compiled three relevant aspects you should further research:

  1. Future Outlook: What are well-informed industry analysts predicting for JNJ’s future growth? Take a look at our free research report of analyst consensus for JNJ’s outlook.
  2. Financial Health: Are JNJ’s operations financially sustainable? Balance sheets can be hard to analyze, which is why we’ve done it for you. Check out our financial health checks here.
  3. Other Attractive Alternatives : Are there other well-rounded stocks you could be holding instead of JNJ? Explore our interactive list of stocks with large potential to get an idea of what else is out there you may be missing!

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

About NYSE:JNJ

Johnson & Johnson

Engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.

Solid track record established dividend payer.

Advertisement

Weekly Picks

ST
stuart_roberts
UG logo
stuart_roberts on Upside Gold ·

An Undervalued 3.3Moz Gold Project in Canada

Fair Value:CA$5.0774.4% undervalued
218 users have followed this narrative
1 users have commented on this narrative
31 users have liked this narrative
SI
SimpleMan887
GME logo
SimpleMan887 on GameStop ·

GameStop will ace the financial crisis wave with its strategic Bitcoin investment and cash reserves

Fair Value:US$22089.4% undervalued
55 users have followed this narrative
2 users have commented on this narrative
21 users have liked this narrative
YI
HSAI logo
yiannisz on Hesai Group ·

The First Real Lidar Winner

Fair Value:US$27.0716.3% undervalued
14 users have followed this narrative
1 users have commented on this narrative
4 users have liked this narrative
TR
tripledub
TSM logo
tripledub on Taiwan Semiconductor Manufacturing ·

The Most Wonderful Monopoly in the Most Dangerous Neighbourhood on Earth

Fair Value:US$3812.7% undervalued
12 users have followed this narrative
0 users have commented on this narrative
13 users have liked this narrative

Updated Narratives

53
RXRX logo
537578 on Recursion Pharmaceuticals ·

Recursion Pharmaceuticals! WTH is going on?

Fair Value:US$1.9766.5% overvalued
8 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
RO
Robbo
V logo
Robbo on Visa ·

Visa and the Case for Patience in Premium Businesses

Fair Value:US$2808.7% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
EV
SSE logo
evadav on SSE ·

Future Prosperity Awaits with SSE's Impressive 11% Revenue Growth

Fair Value:UK£31.7613.3% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TR
tripledub
MSFT logo
tripledub on Microsoft ·

Everyone's Terrified Microsoft Will Keep Spending. I'm Terrified They'll Stop.

Fair Value:US$3956.1% undervalued
45 users have followed this narrative
3 users have commented on this narrative
42 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$587.3136.9% undervalued
1351 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative
RO
Robbo
TSLA logo
Robbo on Tesla ·

The academically fascinating Tesla

Fair Value:US$301.1k% overvalued
37 users have followed this narrative
11 users have commented on this narrative
31 users have liked this narrative